Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Tear Osmolarity and Matrix Metaloproteinase-9 in Primary and Secondary Sjögren’s Syndrome Dry Eye
Author Affiliations & Notes
  • José Francisco Martinez-Delgado
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Fernando Morales-Wong
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Janett L Riega-Torres
    Rheumatology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Alberto Javier Cavazos-Tamez
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Alicia Jocabeth Hernández-Moreno
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Dionicio Galarza-Delgado
    Rheumatology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Jesús Mohamed-Hamsho
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Karim Mohamed-Noriega
    Ophthalmology department, University Hospital, Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, Nuevo Leon, Mexico
  • Footnotes
    Commercial Relationships   José Francisco Martinez-Delgado None; Fernando Morales-Wong None; Janett L Riega-Torres None; Alberto Cavazos-Tamez None; Alicia Jocabeth Hernández-Moreno None; Dionicio Galarza-Delgado None; Jesús Mohamed-Hamsho None; Karim Mohamed-Noriega None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6571. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      José Francisco Martinez-Delgado, Fernando Morales-Wong, Janett L Riega-Torres, Alberto Javier Cavazos-Tamez, Alicia Jocabeth Hernández-Moreno, Dionicio Galarza-Delgado, Jesús Mohamed-Hamsho, Karim Mohamed-Noriega; Tear Osmolarity and Matrix Metaloproteinase-9 in Primary and Secondary Sjögren’s Syndrome Dry Eye. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6571.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Tear osmolarity (Osm) and Matrix metalloproteinase-9 (MMP9) are useful and proven tools in diagnosing dry eye disease (DED), however scarce information exists on their utility for discerning DED etiology. The aim of this study is to evaluate whether in-office Osm and MMP9 tests could aid to differentiate DED associated with primary and secondary Sjogren’s syndrome (pSS and sSS, SS) from patients with rheumatoid arthritis but no SS (non-SS RA) and non-SS DED patients. This is a prospective, consecutive, cross-sectional, and comparative study.

Methods : Data was analyzed from a cohort of rheumatic patients with DED symptoms (2015-2023). Patients aged 18-years or older, with DED symptoms and rheumatic disease were included. Control group consisted of non-rheumatic patients with DED. Osm, MMP9, Ocular Surface Disease Index (OSDI), tear breakup time (TBUT), ocular surface staining (OSS), Schirmer test (ST) and corneal sensitivity (CS) were evaluated. Associations and correlations with Osm, MMP9 and DED etiology were performed (Chi2, Kruskal-Wallis and Kendall’s tau b). Institutional ethics committee approval was received; all participants provided written informed consent.

Results : Positive MMP9 was more frequently observed in pSS (25.3%) and sSS (32.0%) than non-SS RA (6.9%) and controls (9.3%) (p≤0.001), but no significant difference between pSS and sSS was observed. Osm showed no significant difference between study groups: pSS=309(277-398), sSS=306(276-390), non-SS RA=308(282-386), control=301(277-367) (p=0.067). Positive MMP9 patients showed greater OSS in pSS (p≤0.001), sSS (p=0.013) and non-SS RA (p=0.041), but not in controls; reduced CS in non-SS RA (p=0.023) and controls (p=0.049); shorter TBUT (p=0.007) and ST w. and w/o anesthesia (p≤0.001, p=0.011) in pSS; and higher OSDI in controls (p=0.038). Osm showed no association with positive MMP9 in any group (pSS p=0.459, sSS p=0.731, non-SS RA p=0.763, control p=0.638), but was significantly weakly correlated with TBUT (r=-0.107, p=0.005), OSS (r=0.188, p≤0.001), STT w. (r=-0.127, p=0.001) and w/o anesthesia (r=-0.125, p=0.001).

Conclusions : Patients with pSS and sSS have greater percentages of positive MMP9, and it was associated with more severe DED. MMP9 could be used as an adjuvant tool to help identify SS DED and those with worse DED. Tear Osm was weakly correlated with other DED test but was not useful for discerning DED etiology

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×